生物降解的微栓塞与纳米植入的Polyanions使高效药物加载和持续深度瘤药物透为局部区域化学栓塞治疗的药物透
Yutao Ma1,2, Zhihua Li1, Yucheng Luo1
1Shenzhen Key Laboratory of Smart Healthcare Engineering, Guangdong Provincial Key Laboratory of Advanced Biomaterials, Department of Biomedical Engineering, Southern University of Science and Technology, Shenzhen, Guangdong 518055, China.
ACS nano
|July 1, 2024
概括
新的可生物降解微栓塞剂为肝癌治疗提供了改善的药物输送. 这些基于凝的颗粒提供了持续的药物释放和长期的瘤保留,增强了跨动脉化学栓塞的疗效.
科学领域:
- 生物材料科学 生物材料科学
- 在瘤学瘤学.
- 干预性放射学 干预性放射学
背景情况:
- 跨动脉化学栓塞 (TACE) 是不可切除的肝癌的标准.
- 目前的TACE使用的是不可降解的药物,药物释放控制不佳,限制了疗效.
- 需要改进的药物载体,具有持续释放和生物降解性.
研究的目的:
- 为增强TACE开发新的生物降解药物排泄微血栓.
- 创建一个有效的药物加载和受控的长期释放平台.
- 在临床前模型中评估这些微血栓的疗效和安全性.
主要方法:
- 基于凝的微栓塞物被合成并用聚烯酸移植.
- 用多克索鲁比进行静电药物加载,使用对比凝结效应进行.
- 在体内研究包括了猪肝中的微导管输送能力和子VX2肝癌模型中的疗效.
主要成果:
- 高药物负载能力 (>34 mg/mL) 和效率 (>98%) 在不到10分钟的时间内实现.
- 微血栓患者显示药物释放持续超过2个月,瘤透深 (>3毫米).
- 临床前模型证明了有效的瘤杀死,永久栓塞和最低限度的炎症后退化.
结论:
- 可生物降解,离子交换微栓塞为TACE提供了一种多功能策略.
- 这些载体在肝癌治疗中增强了长期治疗反应.
- 开发的平台显示了改善各种局部化疗治疗的前景.
相关概念视频
Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...


